Can Sorafenib be combined with PD1 to treat liver cancer?

Sorafenib (Sorafenib) can be used in combination with PD-1 antibody therapy to treat hepatocellular carcinoma (HCC). PD-1 antibodies are immune checkpoint inhibitors that can activate the immune system to attack tumors by blocking the interaction between the PD-1 receptor and its ligand PD-L1. The combined application of sorafenib and PD-1 antibodies is a promising therapeutic strategy to improve the therapeutic efficacy of patients with hepatocellular carcinoma.

Sorafenib and PD-1 antibodies work on different anti-tumor mechanisms. By targeting multiple signaling pathways at the same time, they can produce a synergistic effect and enhance the anti-tumor effect. Sorafenib can regulate the tumor microenvironment, reduce the number of immunosuppressive cells, and increase the activity of immune cells, thereby improving the efficacy of PD-1 antibodies. Although combination therapy may lead to better clinical results, it needs to be clearly pointed out that combination therapy may also increase the risk of toxic side effects. Transcatheter arterial chemoembolization followed by PD-1 combined with sorafenib is safe and effective in the treatment of advanced HCC, especially for patients who respond well to initial treatment, and can further improve disease prognosis.

The original drug of sorafenib has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around 1,200 yuan. The original drug of sorafenib has also been launched overseas, and there are also generic drugs of sorafenib produced in other countries. The price of 0.2g*60 tablets produced by a Bangladesh pharmaceutical factory is around RMB 450 (the price may fluctuate due to the exchange rate). The ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.